Roth Capital Maintains Buy on Gain Therapeutics, Lowers Price Target to $6
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $7 to $6.
Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $7 to $6.